anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain the subject inhibitor having significant proliferation inhibitory effect against hepatic Ito cells and protein formation inhibitory effect by including crude-drug Scutellarial Radix-derived flavonoid compound(s). SOLUTION: This inhibitor contains at least one kind of crude-drug Scutellarial Radix-derived flavonoid compound (e.g. Baicalein of formula I, Baicalin of formula II, Wogonin of formula III, Wogonoside of formula IV). The inhibitor is pref. if the form of a crude drug, inhibiting hepatic fibrogenesis in chronic hepatopathy involving fibrosis such as chronic hepatitis, its daily dose being 1-2,000 mg/kg, pref. 1-1,000 mg/kg or so.
Prescribe TUXARIN ER for the shortest duration that is consistent with individual patient treatment goals [see Warnings and Precautions (5.1)]

Monitor patients closely for respiratory depression, especially within the first 24-72 hours of initiating therapy [see Warnings and Precautions (5.2)].

Reevaluate patients with unresponsive cough in 5 days or sooner for possible underlying pathology, such as foreign body or lower respiratory tract disease [see Warnings and Precautions (5.5)]. If a patient requires a refill, reevaluate the cause of the cough and assess the need for continued treatment with TUXARIN ER, the relative incidence of adverse reactions, and the development of addiction, abuse, or misuse [see Warnings and Precautions (5.1)].

Do not abruptly discontinue TUXARIN ER in a physically-dependent patient [see Drug Abuse and Dependence (9.3)]. When a patient who has been taking TUXARIN ER regularly and may be physically dependent no longer requires therapy with TUXARIN ER, taper the dose gradually, by 25% to 50% every 2 to 4 days, while monitoring carefully for signs and symptoms of withdrawal. If the patient develops these signs or symptoms, raise the dose to the previous level and taper more slowly, either by increasing the interval between decreases, decreasing the amount of change in dose, or both.
PROBLEM TO BE SOLVED: To provide a germinated unpolished rice enriched with γ-aminobutyric acid and effective for taking the valuable components of unpolished rice such as vitamins, minerals and dietary fibers together with γ-aminobutyric acid and provide flour of germinated unpolished rice enriched with γ-aminobutyric acid and resistant to the deterioration of quality caused by the long-term storage. SOLUTION: Unpolished rice is germinated to obtain rice having enriched γ-aminobutyric acid. The germinated unpolished rice having enriched γ- aminobutyric acid is dried and crushed to obtain flour of germinated unpolished rice enriched with γ-aminobutyric acid. The germination of unpolished rice enriches γ-aminobutyric acid and facilitates the cooking to expand the application field of cooking. The rice can be processed to further increase the variety of foods by drying and crushing the rice in the form of rice flour. The product enables the taking of valuable components of unpolished rice and γ-aminobutyric acid and is storable for a long period without causing the deterioration of quality.
The invention relates to the field of microorganisms, in particular to bacillus licheniformis and application thereof. The deposit number of the bacillus licheniformis is GDMCC No. 62052. The invention also discloses a product composition, which contains the thallus substance and/or metabolite of the bacillus licheniformis. The bacillus licheniformis provided by the invention has killing effect on staphylococcus aureus, escherichia coli, clostridium, salmonella enteritidis and pseudomonas aeruginosa and is dose dependent. The QX8 purified product can inhibit the response of the purple bacillus to the signal factor acetyl homoserine lactone, and in another test, the QX8 purified product has obvious inhibition effect on the purplish red. Compounds produced by Bacillus licheniformis QX8 at low concentrations can also interfere with the cellular response to signal factors and inhibit virulence factor production, preventing biofilm formation.
During the endoscopic examination, patient is sedated with intravenous Dormicum 5mg (5mg/1ml/amp), the vital signs will be closely monitored by physiological monitor (PHILIPS SureSigns VM6). The treatment will be terminated immediately if unstable vital sign detected or if patient asks for termination. Patients will receive test for UFT300 to evaluate H. pylori colonization in the gastric cardia. With endoscope apparatus, the gastric mucous is irrigated with acetylcysteine solution and the pH value of gastric juice will be measured with the pH test strips before irrigation and after irrigation. The investigators dispense medicaments containing Clarithromycin powder (1 gm) on the surface of gastric mucosa and duodenal mucosa of duodenal bulb as evenly as possible. After the intraluminal therapy, patients will rest for 30 to 60 minutes and go home if the effect of sedation subsided. Patients can take meal if no abdominal discomfort. C13-Urea breath test (UBT) will be used to assess the existence of H. pylori 6 weeks after the intraluminal therapy. Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic rescue therapies with triple therapy which contains a proton pump inhibitor and two antibiotics ( amoxicillin and clarithromycin) for 14 days. C13-UBT will be used to assess the existence of H. pylori 6 weeks after the rescue therapy. Overall eradication rates after the first line intraluminal therapy and the oral antibiotics rescue therapies will be evaluated.
There is provided a system and method for managing a case database that can enhance the quality of information to be registered. Once a user performs an operation to request registration of a case, it is first searched whether or not a case that can be determined to be similar to the case has already been registered in a case database. A result of the search is then reported, while executable processing options determined based on the result of the search are also reported. If the case that can be determined to be similar has already been registered, the executable processing options include processing of registering as a new case, processing of registering by adding into an existing case, and processing of cancelling registration. If the case that can be determined to be similar has not been registered, the executable processing options include processing of registering as a new case and processing of cancelling registration. The user selects processing to be executed out of the reported executable processing options. Accordingly, only the cases truly needed by the user can be registered into the case database.
General anesthesia is induced by continuously injecting remimazolam (6 mg/kg/h) and remifentanil (2-6 ng/ml, target concentration controlled infusion) through an infusion pump. Afterwards, when the patient loses consciousness, rocuronium 0.6 mg/kg is injected for endotracheal intubation, and anesthesia is maintained with remimazolam (1-2 mg/kg/hr) and remifentanil after endotracheal intubation. When the surgery is completed, all anesthetic drugs being administered are stopped, and general anesthesia is terminated with flumazenil and sugammadex.
The invention relates to a composition for use in the treatment of the effects of environmental pollution on the skin or for the prevention of premature ageing of the skin associated with the effects of environmental pollution. Said composition comprises diterpenes, oleuropein, verbascoside, quercetin and hydroxytyrosol. In a preferred embodiment, the composition contains approx. 32 wt.% of rosemary extract with a minimum content of 15 wt.% of diterpenes, approx. 30 wt.% of olive leaf or fruit extract with a minimum content of 16 wt.% of oleuropein and a minimum content of 5 wt.% of hydroxytyrosol, approx. 28 wt.% of Lippia citriodora extract with a minimum content of 25 wt.% of verbascoside, and approx. 10 wt.% of Sophora japonica extract with a minimum content of 40 wt.% of quercetin.
Despite the popularity of Cognitive-Behavioral Treatment (CBT) in substance use disorders, recent findings have indicated that CBT may be no more effective than other, less theoretically driven, treatments, and that CBT treatments often fail to result in coping skills acquisition. In order to explore the possibility that current manual-driven modes of CBT delivery may not be adequate to successfully teach coping skills, we are proposing a pilot project for the development of an individualized assessment and cognitive-behavioral treatment program (IATP) for alcohol-dependent persons, in which experience sampling conducted via random calls to cell-phones is used to provide data to create individualized treatment plans. Data collected during experience sampling will include momentary assessments of patients' cognitions, affects, and coping behaviors with respect to drinking.

Participants will be 112 men and women meeting criteria for alcohol dependence, who will be randomly assigned to either a standard packaged manual-driven cognitive-behavioral treatment program (PCBT) like that used in Project MATCH, or to IATP. Patients in both treatments will be asked to engage in experience sampling for two weeks prior to treatment, and for another two weeks after treatment has ended, in order to compare in-vivo measures of coping skills utilization, pre- and posttreatment, between the two groups. Therapy will be conducted over 12 sessions in both treatments. In IATP, the information gathered from experience sampling will form the basis of a functional analysis of patients' drinking and drinking urges during the monitoring period. Cognitive appraisals, moods and coping responses will be evaluated as antecedents and consequences of drinking behavior. Therapists will use the information to address specific cognitions, affects, and behaviors that are adaptive and maladaptive, and will work with the patient to substitute adaptive coping tactics instead. In PCBT the experience sampling data will not be specifically used in therapy, but will still provide in-vivo measures of drinking and coping skills. It is hypothesized that IATP will yield significantly better coping skills acquisition than will PCBT, and that change in coping skills will predict better posttreatment outcomes for IATP. These results would have implications for our delivery of treatment, and for the validity of coping skills training for alcohol addiction.
Provided is a lilium polysaccharide nourishing health care oral liquid in the health product technical field, the lilium polysaccharide is taken as main ingredient of medicament activity, the composition and the weight percentage of the prescription are as follows: 2-3016764762541f lilium polysaccharide PS-W, 0. 1-1016646774326f lilium polysaccharide PS-L, 0. 01-1. 016646774313f lilium polysaccharide and 0. 01-54565500f flavoring agent. The nourishing oral liquid has immunomodulation, anti-senescence, blood sugar-dropping and anti-tumor or the like multiple efficacies, has body building and health care functions for people with low immunologic function and senile decay people, has health care and auxiliary treating actions for diabetic.
BACKGROUND: Although rumen development is crucial, hindgut undertakes a significant role in young ruminants' physiological development. High-starch diet is usually used to accelerate rumen development for young ruminants, but always leading to the enteral starch overload and hindgut dysbiosis. However, the mechanism behind remains unclear. The combination of colonic transcriptome, colonic luminal metabolome, and metagenome together with histological analysis was conducted using a goat model, with the aim to identify the potential molecular mechanisms behind the disrupted hindgut homeostasis by overload starch in young ruminants.
RESULT: Compared with low enteral starch diet (LES), high enteral starch diet (HES)-fed goats had significantly higher colonic pathology scores, and serum diamine oxidase activity, and meanwhile significantly decreased colonic mucosal Mucin-2 (MUC2) protein expression and fecal scores, evidencing the HES-triggered colonic systemic inflammation. The bacterial taxa Prevotella sp. P4-67, Prevotella sp. PINT, and Bacteroides sp. CAG:927, together with fungal taxa Fusarium vanettenii, Neocallimastix californiae, Fusarium sp. AF-8, Hypoxylon sp. EC38, and Fusarium pseudograminearum, and the involved microbial immune pathways including the "T cell receptor signaling pathway" were higher in the colon of HES goats. The integrated metagenome and host transcriptome analysis revealed that these taxa were associated with enhanced pathogenic ability, antigen processing and presentation, and stimulated T helper 2 cell (TH2)-mediated cytokine secretion functions in the colon of HES goats. Further luminal metabolomics analysis showed increased relative content of chenodeoxycholic acid (CDCA) and deoxycholic acid (DCA), and decreased the relative content of hypoxanthine in colonic digesta of HES goats. These altered metabolites contributed to enhancing the expression of TH2-mediated inflammatory-related cytokine secretion including GATA Binding Protein 3 (GATA3), IL-5, and IL-13. Using the linear mixed effect model, the variation of MUC2 biosynthesis explained by the colonic bacteria, bacterial functions, fungi, fungal functions, and metabolites were 21.92, 20.76, 19.43, 12.08, and 44.22%, respectively. The variation of pathology scores explained by the colonic bacterial functions, fungal functions, and metabolites were 15.35, 17.61, and 57.06%.
CONCLUSIONS: Our findings revealed that enteral starch overload can trigger interrupted hindgut host-microbiome homeostasis that led to impaired mucosal, destroyed colonic water absorption, and TH2-mediated inflammatory process. Except for the colonic metabolites mostly contribute to the impaired mucosa, the nonnegligible contribution from fungi deserves more future studies focused on the fungal functions in hindgut dysbiosis of young ruminants. Video Abstract.
BACKGROUND: Up to 85% of patients with sickle cell disease (SCD) will develop gallstones by their third decade. Cholecystectomy is the most commonly performed procedure in these patients. Cholecystectomy is recommended for patients with SCD with symptomatic cholelithiasis and leads to lower morbidity. No contemporary large studies have evaluated this recommendation or associated clinical outcomes. This study evaluates clinical outcomes after cholecystectomy in patients with SCD and cholelithiasis with specific advanced clinical presentations.
STUDY DESIGN: The Nationwide Inpatient Sample was queried for patients with SCD and gallbladder disease between 2006 and 2015. Patients were divided into groups based on their disease presentation, including uncomplicated cholelithiasis, acute and chronic cholecystitis, and gallstone pancreatitis. Clinical outcomes associated with disease presentation were analyzed. Statistical analysis was performed using the Student's t -test, chi-square test, ANOVA, and logistic regression.
RESULTS: There were 6,662 patients with SCD who presented with cholelithiasis. Median age was 20 (interquartile range 16 to 34) years and 54% were female patients. Cholecystectomy was performed in 1,779 patients with SCD with the most common indication being chronic cholecystitis (44%), followed by uncomplicated cholelithiasis (27%), acute cholecystitis (21%), and choledocholithiasis or gallstone pancreatitis (8%). On multivariable regression, advanced clinical presentation was the strongest predictor of perioperative vaso-occlusive crisis, which was the most common complication. Patients undergoing cholecystectomy for uncomplicated cholelithiasis were at lower risk than those with acute cholecystitis (odds ratio [OR] 2.37; 95% CI 1.64 to 3.41), chronic cholecystitis (OR 1.74; 95% CI 1.26 to 2.4), and choledocholithiasis or gallstone pancreatitis (OR 2.24; 95% CI 1.41 to 3.57).
CONCLUSIONS: Seventy-three percent of patients with SCD have advanced clinical presentation at the time of their cholecystectomy. After cholecystectomy, perioperative vaso-occlusive events were significantly increased in patients with advanced clinical presentation. These data support screening abdominal ultrasounds and early cholecystectomy for cholelithiasis in patients with SCD.
A method of reducing respiratory alkalosis (high blood pH) and enhancing productivity (rate of weight gain) in poultry during periods of chronic or acute heat stress (high heat and humidity) involving the steps of supplementing the birds' diet (feedstuffs and/or water) with acids (hydrogen ion donor) and bicarbonate donors (NaHCO3) or supplementing the birds' drinking water with additional potassium ion (e.g. KCl or K2CO3) and/or ammonium chloride with or without NaHCO3 and ascorbic acid. The addition of an acid donor as a poultry feed or water additive and the use of additional potassium in the drinking water significantly reduces the alkalosis induced mortality rate and enhances the rate of weight gain (up to 30 percent). By including NaHCO3 in the feed ration, the rate of gain is further enhanced (an additional 9 percent). The further intention addition of a sodium free, chloride ion donor also promotes increased rate of gain. The use of a H2 antagonist (cimetidine) to reduce stomach acid production is also beneficial to increase growth rate and mortality by reducing blood pH.
OBJECTIVE: To present a novel technique for office resection of pedunculated endometrial polyps under ultrasound guidance.
METHODS: A prospective trial was conducted at an academic center where women with abnormal uterine bleeding (AUB) who were diagnosed an endometrial polyp following saline infusion sonogram (SIS), were offered polyp removal under ultrasound guidance using a universal grasping forceps (2.5 mm × 25 cm). The primary outcome was to evaluate the feasibility of this technique for complete removal of the polyp. The secondary outcomes were to evaluate the patients' pain score, satisfaction score using visual analogue score (VAS), and efficacy of the technique in alleviating symptoms in patients with AUB due to polyps.
RESULTS: Thirty patients participated, with a mean age of 54.8 ± 11 years. Average polyp volume was 1.87 cm3 and mean duration for polypectomy was 11 minutes 31 seconds. The median pain score immediately post-procedure was 5 (0-9). We were unable to complete the procedure in two patients due to patient discomfort and poor visualization. Complete removal of polyp was ensured by checking for a thin endometrial echo at the end of the procedure and by performing SIS at 3-months post-procedure. Of the 22 patients who returned for follow-up, 19 (86.36%) showed no evidence of polyp on SIS and all reported resolution of AUB symptoms. The median satisfaction score at the follow-up was 10/10. Adequate pathology samples were obtained from all cases, diagnosing malignancy in one and endometrial hyperplasia in one patient.
CONCLUSION: This technique offers safe and effective removal of pedunculated endometrial polyps in an office setting, avoiding the need for general anesthesia. It can be offered as a therapeutic option at the initial point of contact, providing symptom relief and tissue diagnosis while reducing costs and patient visits.
Participants will receive low dose chemotherapy as a maintenance therapy post-transplant. Participants must enroll by post-transplant day 40. Treatment will consist of once weekly 5 mg/m2 decitabine followed by 400 mg venetoclax orally approximately 6 hours afterwards. Participants will continue maintenance therapy for one year or unacceptable toxicity. Participants will otherwise receive post Allogeneic hematopoietic stem cell transplant (alloSCT) care and disease monitoring as per institutional standards.
Ulcerative colitis (UC) is a chronic inflammatory bowel disease that slightly reduces life expectancy, strongly reduces its quality and can lead to serious complications such as acute colitis, dysplasia and colon cancer. About 40'000 patients are affected in France Among them, 15% suffer from a chronic active form that often leads to an extended steroid therapy, and its known side effects. Azathioprine has already proven its efficacy in this indication but brings a lasting remission without steroid in only 41% of the patients (1-4). What are the medications available for the patients who failed in maintaining a remission with azathioprine ? Cyclosporin is designed for severe or steroid-resistant forms. (5). The results of two recent studies have showed that infliximab is more efficacious than placebo in active UC (6, 7). Infliximab is expensive, its efficacy in steroid-dependent UC has not been specifically tested yet, and its tolerance on the long term remains uncertain. Methotrexate proved its efficacy in Crohn's disease with an intramuscular dose of 25mg/week (8). In UC a controlled trial has been negative with an oral dose of 12.5mg/week (9). Another study compared mercaptopurine, methotrexate (15mg/week) and 5-aminosalicylate in 72 steroid-dependent patients with CD or UC (10). The remission rates obtained were 58% after 30 weeks with methotrexate (not significantly different from 5-ASA) and 14% after 106 weeks (not significantly different from 5-ASA). Few data are available on the efficacy of methotrexate in UC, at a dose which is active in Crohn's disease (25mg intramuscular/week). Several uncontrolled series have been published, including 91 patients whose remission failed under azathioprine.

Methotrexate is cheap and its patent has fallen in the public domain. Only institutional research will be able to finance a study in this new indication.

This is a prospective, controlled, randomized, double-blind study of methotrexate with an intramuscular dose of 25mg/week vs placebo in patients with steroid-dependent UC.

This multicenter study will take place under the aegis of the Therapeutic Study Group for Inflammatory Digestive Diseases (G.E.T.A.I.D.) and with the help of the gastroenterologists network of the CIC. The issue of this study is important. If the hypothesis is borne out, a cheap, efficacious medication will be available for chronic active UC.
PURPOSE: A disposable container for mixing cosmetics is provided to allow different kinds of materials to be introduced into a main body. CONSTITUTION: A disposable container for mixing cosmetics includes a main body (110), a mixing unit (120), and an opening and closing unit (130). The main body has at least one discharge hole and is formed with an open internal space. Ampules containing raw materials inserted into an ampule insertion holes. The mixing unit mixes two or more kinds of raw materials stored in the internal space. The opening and closing unit has an outlet and connects to the bottom of the main body to discharge the mixed raw materials to the outside.
FIELD: genetic engineering. SUBSTANCE: transgenic plants are obtained and their seeds are added to reacting mixture containing a substrate and an enzyme. Seeds are added as a ground form directly. Form of product ensures to use its for treatment as a food ration. For preparing transgenic plants plasmids are used. Invention can be used for preparing enzymes and in food production. EFFECT: decreased cost due to increase of fermentation rate, simplified extraction and purification of product. 16 cl, 13 dwg, 3 tbl, 16 ex
FIELD: medicine, gynecology. SUBSTANCE: at the background of medicinal therapy one should conduct intravascular blood irradiation with He-Ne laser for 20-30 min. Laser radiation power does nor exceed 1 mW at 0.63 mcm wave length. Moreover, 60 min before laser impact it is necessary to introduce an ozonized physiological solution. Concentration of dissolved ozone corresponds to 1-2 mg/l. Therapy is conducted daily once/d at one and the same period of time. Treatment course consists of 7-10 seances. The method enables to increase and prolong curative effect of conservative therapy in women of reproductive age. EFFECT: higher efficiency.